Brief: Theravance Biopharma Inc QTRLY Loss Per Share $0.11

Theravance Biopharma

04/08/2022 22:28

Theravance Biopharma Inc  TBPH.O :
    * THERAVANCE BIOPHARMA, INC. REPORTS SECOND QUARTER 2022
FINANCIAL
RESULTS AND PROVIDES BUSINESS UPDATE
    * THERAVANCE BIOPHARMA INC - TOTAL REVENUE FOR Q2 OF 2022
WAS
$11.1 MILLION
    * THERAVANCE BIOPHARMA INC - TOTAL REVENUE FOR Q2 REPRESENTS
A
$1.9 MILLION DECREASE OVER SAME PERIOD IN 2021
    * THERAVANCE BIOPHARMA INC - CASH, CASH EQUIVALENTS AND
MARKETABLE
SECURITIES TOTALED $132.9 MILLION AS OF JUNE 30, 2022.
    * THERAVANCE BIOPHARMA INC - COMPANY EXPECTS TO APPROACH
BREAKEVEN
CASH FLOW FROM OPERATIONS IN 2H 2022
    * THERAVANCE BIOPHARMA INC - COMPANY EXPECTS FULL YEAR 2022
RESEARCH AND DEVELOPMENT EXPENSE OF $45 MILLION TO $55 MILLION
    * THERAVANCE BIOPHARMA INC QTRLY LOSS PER SHARE $0.11

Source text for Eikon:  ID:nPn5ytYGsa 
Further company coverage:  TBPH.O